3 days popular7 days popular1 month popular3 months popular

Clinical evaluation of teriparatid treatment for osteogenesis imperfecta

Patients with (OI) are prone to bone fracture and skeletal deformity, and for these patients are severely limited.

In this issue of the , and colleagues at evaluated the use of the teriparatide, a recombinant human parathyroid hormone, for patients with OI.

Compared with patients taking placebo, taking tripartite exhibited increased bone density; however, this effect was limited to patients with a mild form of disease.

In an accompanying Attending Physician article, Nick Bishop of the University of Sheffield and Jennifer Walsh of the Metabolic Bone Centre caution that despite the apparent improvement observed with teriparatide treatment, the best course of action for OI patients is supportive care to limit damage.

TITLE: Osteogenesis imperfecta in adults

ACCOMPANYING THE ATTENDING PHYSICIAN

TITLE: Osteogenesis imperfecta in adults

Source

Journal of Clinical Investigation